The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant
4.8
(754)
Write Review
More
$ 17.50
In stock
Description
β-Escin overcomes trastuzumab resistance in HER2-positive breast
A novel HSP90 inhibitor SL-145 suppresses metastatic triple
Cancers, Free Full-Text
New ruthenium-xanthoxylin complex eliminates colorectal cancer
PDF) A novel HSP90 inhibitor SL-145 suppresses metastatic triple
Salinomycin decreases the CD44+/CD24- stem-like population during
New ruthenium-xanthoxylin complex eliminates colorectal cancer
PDF) A novel HSP90 inhibitor SL-145 suppresses metastatic triple
PDF) A novel HSP90 inhibitor SL-145 suppresses metastatic triple
Following the design path of isoform-selective Hsp90 inhibitors
The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant
Related products
